Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.92 Billion SEK | -0.54% |
| 2022 | 5.72 Billion SEK | -3.71% |
| 2021 | 6.19 Billion SEK | -16.42% |
| 2020 | 6.46 Billion SEK | 51.51% |
| 2019 | 4.53 Billion SEK | 204.06% |
| 2018 | 1.6 Billion SEK | -66.74% |
| 2017 | 3.41 Billion SEK | 33.77% |
| 2016 | 3.26 Billion SEK | 5.73% |
| 2015 | 3.4 Billion SEK | -11.21% |
| 2014 | 3.83 Billion SEK | -7.5% |
| 2013 | 4.14 Billion SEK | -1.4% |
| 2012 | 4.2 Billion SEK | 2.14% |
| 2011 | 4.11 Billion SEK | 5.94% |
| 2010 | 3.88 Billion SEK | 6.35% |
| 2009 | 3.65 Billion SEK | -77.53% |
| 2008 | 16.26 Billion SEK | 401.54% |
| 2007 | 3.24 Billion SEK | 39.91% |
| 2006 | 2.27 Billion SEK | 8.2% |
| 2005 | 2.14 Billion SEK | 5.34% |
| 2004 | 2.03 Billion SEK | 415.11% |
| 2003 | -645.4 Million SEK | -39.09% |
| 2002 | -464 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.39 Billion SEK | 14.11% |
| 2024 Q3 | 861 Million SEK | -38.46% |
| 2024 Q1 | 1.22 Billion SEK | -34.19% |
| 2023 Q1 | 1.4 Billion SEK | -19.62% |
| 2023 Q4 | 1.86 Billion SEK | -11.16% |
| 2023 Q3 | 2.09 Billion SEK | 117.08% |
| 2023 Q2 | 966 Million SEK | -31.05% |
| 2023 FY | - SEK | -0.54% |
| 2022 Q2 | 1.35 Billion SEK | 7.9% |
| 2022 Q1 | 1.25 Billion SEK | -7.87% |
| 2022 FY | - SEK | -3.71% |
| 2022 Q4 | 1.74 Billion SEK | 9.48% |
| 2022 Q3 | 1.59 Billion SEK | 17.75% |
| 2021 Q1 | 1.58 Billion SEK | -21.81% |
| 2021 FY | - SEK | -16.42% |
| 2021 Q2 | 1.67 Billion SEK | 5.54% |
| 2021 Q3 | 1.54 Billion SEK | -7.88% |
| 2021 Q4 | 1.36 Billion SEK | -11.92% |
| 2020 Q3 | 2.45 Billion SEK | 33.75% |
| 2020 FY | - SEK | 51.51% |
| 2020 Q2 | 1.83 Billion SEK | 73.96% |
| 2020 Q1 | 1.05 Billion SEK | -41.53% |
| 2020 Q4 | 2.03 Billion SEK | -17.34% |
| 2019 Q4 | 1.8 Billion SEK | 67.38% |
| 2019 Q3 | 1.07 Billion SEK | -1.37% |
| 2019 Q1 | 892 Million SEK | -45.97% |
| 2019 FY | - SEK | 204.06% |
| 2019 Q2 | 1.09 Billion SEK | 22.65% |
| 2018 Q3 | -1.13 Billion SEK | -234.4% |
| 2018 FY | - SEK | -66.74% |
| 2018 Q1 | 242 Million SEK | 1.68% |
| 2018 Q2 | 846 Million SEK | 249.59% |
| 2018 Q4 | 1.65 Billion SEK | 245.21% |
| 2017 Q4 | 238 Million SEK | -82.5% |
| 2017 Q3 | 1.36 Billion SEK | -25.23% |
| 2017 FY | - SEK | 33.77% |
| 2017 Q2 | 1.81 Billion SEK | 29.93% |
| 2017 Q1 | 1.4 Billion SEK | 88.43% |
| 2016 Q4 | 743 Million SEK | -51.28% |
| 2016 Q1 | 578 Million SEK | -52.23% |
| 2016 Q2 | 755 Million SEK | 30.62% |
| 2016 FY | - SEK | 5.73% |
| 2016 Q3 | 1.52 Billion SEK | 101.99% |
| 2015 FY | - SEK | -11.21% |
| 2015 Q4 | 1.21 Billion SEK | 42.19% |
| 2015 Q3 | 851 Million SEK | 36.82% |
| 2015 Q2 | 622 Million SEK | -13.49% |
| 2015 Q1 | 719 Million SEK | -20.46% |
| 2014 Q1 | 1.34 Billion SEK | -12.8% |
| 2014 FY | - SEK | -7.5% |
| 2014 Q4 | 904 Million SEK | 11.47% |
| 2014 Q3 | 811 Million SEK | 4.38% |
| 2014 Q2 | 777 Million SEK | -42.1% |
| 2013 Q4 | 1.53 Billion SEK | 93.58% |
| 2013 FY | - SEK | -1.4% |
| 2013 Q3 | 795 Million SEK | -14.61% |
| 2013 Q2 | 931 Million SEK | 5.56% |
| 2013 Q1 | 882 Million SEK | -48.69% |
| 2012 Q2 | 869 Million SEK | 23.44% |
| 2012 Q3 | 915 Million SEK | 5.29% |
| 2012 Q4 | 1.71 Billion SEK | 87.87% |
| 2012 FY | - SEK | 2.14% |
| 2012 Q1 | 704 Million SEK | -59.68% |
| 2011 Q3 | 805 Million SEK | -8.11% |
| 2011 FY | - SEK | 5.94% |
| 2011 Q1 | 690 Million SEK | -53.13% |
| 2011 Q4 | 1.74 Billion SEK | 116.89% |
| 2011 Q2 | 876 Million SEK | 26.96% |
| 2010 Q3 | 864 Million SEK | -0.46% |
| 2010 Q2 | 868 Million SEK | 27.09% |
| 2010 Q1 | 683 Million SEK | -54.92% |
| 2010 FY | - SEK | 6.35% |
| 2010 Q4 | 1.47 Billion SEK | 70.37% |
| 2009 FY | - SEK | -77.53% |
| 2009 Q3 | 872 Million SEK | 22.99% |
| 2009 Q4 | 1.51 Billion SEK | 73.74% |
| 2009 Q1 | 558 Million SEK | 0.0% |
| 2009 Q2 | 709 Million SEK | 27.06% |
| 2008 FY | - SEK | 401.54% |
| 2007 FY | - SEK | 39.91% |
| 2006 FY | - SEK | 8.2% |
| 2005 FY | - SEK | 5.34% |
| 2004 FY | - SEK | 415.11% |
| 2003 FY | - SEK | -39.09% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 7787.819% |
| ADDvise Group AB (publ) | 411.9 Million SEK | -1339.427% |
| ADDvise Group AB (publ) | 411.9 Million SEK | -1339.427% |
| Arcoma AB | 6.24 Million SEK | -94794.366% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 6689.096% |
| BICO Group AB (publ) | 322.3 Million SEK | -1739.59% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | -8886.193% |
| CellaVision AB (publ) | 207.24 Million SEK | -2760.865% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 8767.369% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 21318.196% |
| C-Rad AB (publ) | 48.9 Million SEK | -12023.753% |
| Duearity AB (publ) | -24.77 Million SEK | 24027.519% |
| Dignitana AB (publ) | -264 Thousand SEK | 2245933.333% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 6860.547% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 8916.349% |
| Iconovo AB (publ) | -35.33 Million SEK | 16879.176% |
| Integrum AB (publ) | 8.76 Million SEK | -67570.837% |
| Luxbright AB (publ) | -23.86 Million SEK | 24942.107% |
| Mentice AB (publ) | 28.87 Million SEK | -20434.756% |
| OssDsign AB (publ) | -122.02 Million SEK | 4959.0% |
| Paxman AB (publ) | 31.22 Million SEK | -18885.558% |
| Promimic AB (publ) | -3.68 Million SEK | 161039.24% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 4039.404% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 11539.542% |
| ScandiDos AB (publ) | -13.35 Million SEK | 44492.034% |
| Sectra AB (publ) | 615.06 Million SEK | -863.971% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 11573.856% |
| Senzime AB (publ) | -118.82 Million SEK | 5089.775% |
| SpectraCure AB (publ) | -20.96 Million SEK | 28375.073% |
| Stille AB | 56.04 Million SEK | -10479.754% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 286.154% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | -4584.216% |